| 臺大學術典藏 |
2021-05-07T05:13:24Z |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection
|
Liou J.-M.; Chen P.-Y.; Luo J.-C.; Lee J.-Y.; CHING-CHOW CHEN; Fang Y.-J.; Yang T.-H.; Chang C.-Y.; Bair M.-J.; Chen M.-J.; Hsu Y.-C.; Hsu W.-F.; Chang C.-C.; Lin J.-T.; Shun C.-T.; El-Omar E.M.; Wu M.-S.; Liou J.-M.; Lee Y.-C.; Lin J.-T.; Wu C.-Y.; Wu J.-Y.; CHING-CHOW CHEN; Lin C.-H.; Fang Y.-R.; Bair M.-J.; Luo J.-C.; Cheng T.-Y.; Tseng P.-H.; Chiu H.-M.; Chang C.-C.; Yu C.-C.; Chiu M.-C.; Chen Y.-N.; Hu W.-H.; Chou C.-K.; Tai C.-M.; Lee C.-T.; Wang W.-L.; Chang W.-S.; Taiwan Gastrointestinal Disease and Helicobacter Consortium |
| 臺大學術典藏 |
2021-05-07T02:06:14Z |
Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: A multicentre clinical trial
|
Liou J.-M.; Chen C.-C.; Chang C.-Y.; Chen M.-J.; Fang Y.-J.; Lee J.-Y.; Chen C.-C.; Hsu S.-J.; Hsu Y.-C.; Tseng C.-H.; Tseng P.-H.; Chang L.; Chang W.-H.; Wang H.-P.; Shun C.-T.; Wu J.-Y.; Lee Y.-C.; Lin J.-T.; Wu M.-S.; Lin C.-H.; Chow L.-P.; Cheng T.-Y.; Wu C.-Y.; Lee Ching-Tai C.-T, Wang W.-L.; Tai C.-M.; Wang Y.-C.; CHIH-HSIEN WANG; Kuo S.-H.; Wu C.-Y. |
| 朝陽科技大學 |
2021-05 |
Antibacterial efficacy of quaternized chitosan/poly (vinyl alcohol) nanofiber membrane crosslinked with blocked diisocyanate
|
劉炳嵐; Chang, Y.-K.; Chiu, C.-Y.; Liu, B.-L.; Lin, G.-Y.; Song, C.P.; Wang, C.-Y.; Ooi, C.W.; Wu, J.-Y. |
| 臺大學術典藏 |
2021-04-29T05:09:15Z |
Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer
|
Wu J.-Y.; Shih J.-Y.; Yang C.-H.; KUAN-YU CHEN; Ho C.-C.; Yu C.-J.; Yang P.-C. |
| 臺大學術典藏 |
2021-04-29T05:09:12Z |
Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations
|
Wu J.-Y.; Shih J.-Y.; KUAN-YU CHEN; Yang C.-H.; Yu C.-J.; Yang P.-C. |
| 臺大學術典藏 |
2021-03-29T06:08:21Z |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial
|
Liou, J.-M.; Chen, C.-C.; Chang, C.-M.; Fang, Y.-J.; Bair, M.-J.; Chen, P.-Y.; Chang, C.-Y.; Hsu, Y.-C.; Chen, M.-J.; Chen, C.-C.; Lee, J.-Y.; Yang, T.-H.; Luo, J.-C.; Chen, C.-Y.; Hsu, W.-F.; Chen, Y.-N.; Wu, J.-Y.; Lin, J.-T.; Lu, T.-P.; Chuang, E.Y.; El-Omar, E.M.; Wu, M.-S.; ERIC YAO-YU CHUANG |
| 臺大學術典藏 |
2021-03-19T06:57:51Z |
First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer
|
Wu J.-Y.; Yu C.-J.; Yang C.-H.; Wu S.-G.; Chiu Y.-H.; Gow C.-H.; YEUN-CHUNG CHANG; Hsu Y.-C.; Wei P.-F.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2021-03-19T06:57:46Z |
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer
|
Wu J.-Y.;Yu C.-J.;Yeun-Chung Chang;Yang C.-H.;Shih J.-Y.;Yang P.-C.; Wu J.-Y.; Yu C.-J.; YEUN-CHUNG CHANG; Yang C.-H.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2021-03-19T06:57:46Z |
Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations
|
Wu J.-Y.;Wu S.-G.;Yang C.-H.;Chang Y.-L.;Yeun-Chung Chang;Hsu Y.-C.;Shih J.-Y.;Yang P.-C.; Wu J.-Y.; Wu S.-G.; Yang C.-H.; Chang Y.-L.; YEUN-CHUNG CHANG; Hsu Y.-C.; Shih J.-Y.; Yang P.-C. |
| 臺大學術典藏 |
2021-03-19T06:57:39Z |
Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis
|
Wu S.-G.;Hu F.-C.;Chang Y.-L.;Lee Y.-C.;Yu C.-J.;Yeun-Chung Chang;Wu J.-Y.;Shih J.-Y.;Yang P.-C.; Wu S.-G.; Hu F.-C.; Chang Y.-L.; Lee Y.-C.; Yu C.-J.; YEUN-CHUNG CHANG; Wu J.-Y.; Shih J.-Y.; Yang P.-C. |
